Akums Drugs board approves unaudited results for quarter ended 30 June 2026
Akums Drugs & Pharmaceuticals · Pharmaceuticals & Biotechnology
Key highlights
- Board approved unaudited standalone and consolidated financial results for quarter ended 30 June 2026 on 8 August 2026.
- Income tax search ran 15-21 January 2025; consolidated demand of 1,560.18 million for block period to 12 March 2025 is under appeal; 47.01 million deposited under protest.
- Final dividend of 1 per share and special dividend of 2 per share, aggregate 3 per share, for FY2025-26 approved at AGM held on 10 July 2026.
Why it's rated major development: the year-on-year change is 56% (50% or more)
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Un-Audited Financial Results For The Quarter Ended 30Th June, 2026
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Akums Drugs & Pharmaceuticals
- Acquisition / mergerMajor developmentAkums Drugs reports Q2 FY27 results and acquires Oriflame India's manufacturing business
- Financial resultsMajor developmentAkums Drugs approves June 2026 quarter results; consolidated tax demand of 560.8 million raised
- Financial resultsMajor development· Adverse for the businessAkums Drugs approves audited FY26 results, recommends dividends, changes senior management
- Dividend / buyback / bonusMajor development· Adverse for the businessAkums Q4 net profit ₹813.42 million vs ₹1,496.06 million; ₹3 dividend recommended
- Dividend / buyback / bonusMajor development· Adverse for the businessAkums Drugs approves FY 2026 results, appoints auditors, and announces dividends
Other financial results filings this fortnight
- Siddhika Coatings Limited approves joint venture and announces H1 FY 2026 financials
- Financial resultsBrooks LaboratoriesBrooks Laboratories Limited announces Q2 and H1 FY2026 unaudited financial results
- Financial resultsBrooks LaboratoriesBrooks Laboratories Limited announces Q2 and H1 FY2027 financial results and divestment
- NHC Foods reports Sept 2026 quarter results, 99.98% firm stake, two appointments
- Spectrum Electrical Industries Ltd approves Q2 & H1 results for period ended September 30, 2026
- Dev Labtech Venture reports unaudited half-year results to 30 Sept 2026
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.